Travere Therapeutics, Inc.
TVTX
$62.14
$0.711.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.46M | -21.42M | -25.55M | -88.54M | -169.06M |
| Total Depreciation and Amortization | 63.37M | 73.15M | 60.74M | 54.70M | 50.15M |
| Total Amortization of Deferred Charges | 1.64M | 1.64M | 1.64M | 1.73M | 1.73M |
| Total Other Non-Cash Items | 72.44M | 21.66M | 14.94M | 32.77M | 30.41M |
| Change in Net Operating Assets | -1.29M | -35.42M | -14.00M | -59.26M | -28.67M |
| Cash from Operations | 92.70M | 39.61M | 37.78M | -58.61M | -115.44M |
| Capital Expenditure | 235.00K | 235.00K | 235.00K | -58.00K | 82.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -203.22M | 7.92M | 27.66M | 52.48M | 11.88M |
| Cash from Investing | -202.99M | 8.15M | 27.89M | 52.42M | 11.96M |
| Total Debt Issued | 525.00M | -- | -- | -- | -- |
| Total Debt Repaid | -419.79M | -68.90M | -68.90M | -68.90M | -- |
| Issuance of Common Stock | 66.22M | 38.02M | 37.54M | 149.98M | 146.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -18.37M | -2.10M | -2.10M | -2.10M | -2.10M |
| Cash from Financing | 153.06M | -32.98M | -33.47M | 78.97M | 144.36M |
| Foreign Exchange rate Adjustments | -194.00K | 1.68M | 2.29M | 1.74M | 1.99M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.58M | 16.47M | 34.50M | 74.52M | 42.86M |